• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Dendreon Corp

NASDAQ:DNDN

$7.11 -$0.11 (-1.52%)

REAL-TIME: Last trade at

Dendreon Announces Webcast Presentations at Upcoming Conferences

Dendreon Announces Webcast Presentations at Upcoming Conferences

Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 1

Dendreon Falls as Analyst Starts Coverage

Dendreon falls as analyst starts coverage

Dendreon falls as analyst starts coverage

Darling Dendreon Takes Hits As Speculators Continue To Bet On Immunotherapy Plays

Canaccord Genuity Maintains a 'Hold' on Dendreon (DNDN) After Meeting with Management

Top Analyst Upgrades & Downgrades (AMAT, ARBA, BX, CPLA, CHA, DELL, DNDN, EMC, FB, GMT, ICE, JAZZ, NDAQ, PCX, PG, SBUX, WY)

Dendreon initiated with an Underperform at Jefferies

Dendreon Presents Provenge Data - Analyst Blog

Dendreon Presents Provenge Data

Dendreon has a conference call hosted by JP Morgan

Some Added Hope For Dendreon

Interest Growing In Cancer Stem Cell Biotechs

Dendreon Announces Data Presentation at the 2012 American Urological Association Annual Meeting

What You Must Know Before Investing in Prostate Cancer Stocks

Dendreon says PROVENGE exploratory analysis suggested positive effect

Dendreon Announces Data Presentation at the 2012 American Urological Association Annual Meeting

24/7 Wall St. Closing Bell — May 18, 2012

Dendreon: Timing Of News Story Release Is Interesting

SEC Investigating Dendreon

Dendreon shares fall; SEC probe, rival drug may be reasons

Deutsche Bank's biotech analyst to hold a conference call

Top Analyst Upgrades & Downgrades (ANGI, RATE, IRE, DNDN, LVS, LNKD, MU, MS, PSX, CRM, SNDK, S, TUP, YELP)

Biotech Industry Booming in 2012

Dendreon initiated with a Sell at Maxim

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

Dendreon stock dives after rival's cancer drug shows benefits

24/7 Wall St. Closing Bell — May 17, 2012

Dendreon Down, Ctrip.com Up

Dendreon In Trouble

Dendreon Draws Put Buyers After SEC Probe

Dendreon sinks on news of SEC probe, positive competitor study

Dendreon weakness overdone, says Deutsche Bank

Dendreon falls 12.7%

Dendreon gaps down sharply in early trading, support is at $7.75

Dendreon Provenge: 13 Month Median Extended Survival For PSA 22.1 Or Less

Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting

See More Articles...